DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Study of Dexamethasone-Allantoin-Metronidazole (DAM) Solution in the Treatment of Post-Operative Ileus (POI)

Information source: Beijing Bozhiyin T&S Co., Ltd.
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Postoperative Ileus

Intervention: DAM (Drug); Normal Saline (Drug)

Phase: Phase 3

Status: Recruiting

Sponsored by: Beijing Bozhiyin T&S Co., Ltd.

Official(s) and/or principal investigator(s):
Ying-jiang Ye, professor, Principal Investigator, Affiliation: The people's hospital of Beijing university

Overall contact:
Qing-shan Zheng, professor, Phone: 13817078595, Email: qingshan.zheng@drugchina.net


This study is being conducted to determine whether Dexamethasone-Allantoin-Metronidazole (DAM) Solution can accelerate recovery of gastrointestinal function following abdominal operation when compared with a placebo.

Clinical Details

Official title: A Phase 3, Multicenter, Double-Blind, Placebo-Controlled, Parallel Study of Dexamethasone-Allantoin-Metronidazole (DAM) Solution in the Treatment of Post-Operative Ileus (POI) in Subjects Undergoing Abdominal Operation

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: Time to achieve recovery of both upper and lower GI function as measured by a composite endpoint of time to the first bowel movement and time to tolerate first solid food. This endpoint is referred to as GI2.

Secondary outcome:

Time to ready for discharge

Time to the first flatus

Comparison between the 2 groups of analgesics (morphine) dose

peritoneal exudate volume of 72 hours after operation

C reactive protein changes from baseline

Detailed description: Postoperative ileus (POI) is temporary slowing down or stopping of bowel function and a slowing down of movement of contents of the intestines. This functional impairment persists for a variable duration following surgery, usually resolving within 1 day in the small intestine, 1 to 3 days in the stomach and 3 to 5 days in the colon. When POI persists for more than 5 days, it is generally considered severe, sometimes referred to as complicated or prolonged POI, and increases the risk for related morbidity. This is a randomized, controlled, double-blind study designed to evaluate the tolerability and efficacy of DAM solution for the treatment of POI in patients following abdominal operation. It will be conducted at multiple centers in China. A total of 480 patients will be enrolled in the study. Patient participation in the study will last for up to postoperative day 7 [POD 7] , with follow-up safety assessments to occur 7 days after the operation. The treatment outcome measures include: 1) GI2(Time to achieve recovery of both upper and lower GI function as measured by a composite endpoint of time to the first bowel movement and time to tolerate first solid food). 2) Time to ready for discharge. 3) Time to the first flatus.


Minimum age: 18 Years. Maximum age: 75 Years. Gender(s): Both.


Inclusion Criteria:

- are either Male or Female at least 18 years of age;

- Had an American Society of Anesthesiologists (ASA) Physical Status Score of I-III;

- Were scheduled to undergo partial small or large BR with primary anastomosis

(performed completely by laparotomy); biliary-enteric Roux-en-Y anastomosis surgery;

- BMI (kg/m^2) index≥15 and ≤30;

- Understood the procedures, agreed to participate in the study program, and

voluntarily signed the informed consent form. Exclusion Criteria:

- Had complete bowel obstruction;

- Were scheduled for a total colectomy;

- Were scheduled for a ileal pouch-anal anastomosis;

- Were scheduled for a colostomy, ileostomy;

- Had a history of gastrectomy, total colectomy, gastric bypass, short bowel syndrome,

or multiple previous abdominal surgeries;

- Had clinically significant laboratory abnormalities on screening(such as: ALT, AST

were more than 2 times the upper limit of normal value; Cr is greater than 1. 2 times the upper normal limit, according to the center for the study of the normal value range);

- Applied the intravenous or epidural postoperative analgesia pump;

- Bowel preparation does not meet the requirements;

- Were allergy to components of the investigational drug (allantoin, metronidazole,


- Had used illicit drugs or had abused alcohol;

- Had a history of illness, or behavior (e. g., depression, psychosis) that in the

opinion of the investigator might confound the results of the study or pose an additional risk in participating in the study;

- Women who were pregnant, and women who were of childbearing potential and not using

method of birth control;

- Had participated in another clinical drug trial within the last 3 months;

- Were not agreed to participate the clinical trial by investigators.

Locations and Contacts

Qing-shan Zheng, professor, Phone: 13817078595, Email: qingshan.zheng@drugchina.net

Center for Drug Clinical Research, Shanghai University of Chinese Medicine, Shanghai, Shanghai 201203, China; Recruiting
Additional Information

Starting date: April 2013
Last updated: May 28, 2013

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017